Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Phase4 Partners, formerly known as Nomura Phase4 Ventures, is a venture capital firm based in London, United Kingdom. Founded to invest in companies that are transforming healthcare, the firm has established a strong reputation in the life sciences sector. The team spun out from Nomura in 2015, retaining a portion of assets under management that were subsequently sold to HarbourVest Partners. This transition marked a significant milestone in the firm’s evolution, allowing it to operate independently while continuing to focus on innovative healthcare solutions.
Currently, Phase4 Partners manages a team of eight professionals, including Managing Partner Denise Pollard-Knight, who has a notable background in healthcare venture capital. The firm primarily invests in mid-to-late stage companies, emphasizing biotechnology, medical devices, digital health, and diagnostics. Although specific assets under management are not disclosed, the firm has made over 30 investments since its inception, collaborating with top-tier US and European venture capital firms.
Phase4 Partners is located at 4th Floor, Cavendish Place, London W1G 0QF, England. The firm’s focus on healthcare innovation positions it as a key player in the UK market, where it seeks to support companies that enhance patient care and improve health outcomes.
Phase4 Partners specializes in mid-to-late stage investments within the life sciences sector, particularly in biotechnology, medical devices, digital health technologies, and diagnostics. The firm seeks to partner with companies that are at the forefront of healthcare innovation, focusing on therapies, next-generation devices, and AI-driven diagnostics. Typical check sizes range from $15 million to $30 million, with portfolio company valuations at entry typically between $50 million and $100 million.
The firm operates primarily in the UK market but collaborates with leading venture capital firms across Europe and the US to maximize the impact of its investments. Phase4 Partners employs a co-investment model, often participating alongside other top-tier VCs rather than leading rounds. This collaborative approach allows the firm to leverage its extensive network and deep expertise in life sciences to identify and nurture promising ventures.
Phase4 Partners has built a notable portfolio of companies within the life sciences sector. Key portfolio companies include:
These companies represent a diverse range of innovative solutions aimed at improving healthcare outcomes. Phase4 Partners' investment strategy emphasizes supporting firms that are developing transformative therapies and technologies in the healthcare space.
Denise Pollard-Knight - Managing Partner. Denise has a distinguished career in healthcare venture capital, having previously worked at Nomura Phase4 Ventures. She has been recognized with the Women in the City Award in 2008 for her contributions to the industry. Denise's expertise spans various aspects of life sciences investing, making her a key figure in guiding Phase4 Partners' investment strategy.
To pitch Phase4 Partners, founders should send an email to denise@p4p.tech. It is recommended to include a comprehensive pitch deck that outlines the business model, market opportunity, competitive landscape, and team qualifications. The firm appreciates clear and concise presentations that effectively communicate the startup's vision and potential.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions through mutual connections can enhance the likelihood of a timely response.
As of April 2023, Phase4 Partners has continued to focus on mid-to-late stage investments in the life sciences sector. The firm has made over 30 investments since its inception, collaborating with top-tier US and European VCs. Recent activity includes participation in funding rounds for companies developing innovative healthcare solutions.
Phase4 Partners remains committed to supporting transformative healthcare companies, leveraging its extensive network and expertise to drive advancements in the sector.
What are Phase4 Partners' investment criteria?
Phase4 Partners focuses on mid-to-late stage companies in the life sciences sector, particularly in biotechnology, medical devices, digital health, and diagnostics. The firm looks for companies that are developing innovative solutions that can significantly impact patient care and health outcomes.
How can I apply or pitch to Phase4 Partners?
Founders can reach out to Phase4 Partners via email at denise@p4p.tech. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and team background.
What makes Phase4 Partners different from other venture capital firms?
Phase4 Partners distinguishes itself through its deep expertise in life sciences and its collaborative investment approach. The firm often co-invests with leading venture capital firms, allowing it to leverage a broader network and resources to support portfolio companies.
What is the geographic scope of Phase4 Partners' investments?
The firm primarily focuses on the UK market but actively collaborates with top-tier venture capital firms in Europe and the US, enhancing its reach and impact in the life sciences sector.
What is the typical check size for investments?
Phase4 Partners typically invests between $15 million and $30 million per company, depending on the stage and potential of the investment opportunity.
What kind of post-investment involvement does Phase4 Partners have?
The firm provides strategic guidance and support to its portfolio companies, leveraging its extensive network in the healthcare sector to facilitate partnerships and growth opportunities.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.